About this trial
Psychotic disorders, including schizophrenia and affective psychosis, are severe mental health conditions marked by recurrent episodes that contribute to long-term disability. Relapses, characterized by the re-emergence of psychotic symptoms after remission, are a critical factor in the progression of these disorders, increasing risks such as suicide, cognitive impairment, and unemployment. This study aims to develop a novel, speech-based digital model to predict relapses in individuals with psychosis. Building on previous research into language abnormalities in schizophrenia, the study will employ a longitudinal design across Early Psychosis Intervention (EPI) clinics in Ontario and Quebec to advance relapse prediction
Eligibility criteria
Qualifiers
Age must be 16 years and older
Diagnosis must meet DSM-5 criteria for psychotic disorders, including schizophrenia, schizoaffective disorder, or related conditions
Fluency in English or French
Must be currently receiving treatment through an EPI program
Disqualifiers
Severe comorbid speech or language disorders (e.g., aphasia)
Primary diagnosis of non-psychotic disorders
Inability to provide consent or complete assessments
Trial design
Treatments tested in this trial
- Not listed